查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1500121

精密诊断市场 - 全球产业规模、份额、趋势、机会和预测，按类型、应用、最终用途、地区和竞争细分，2019-2029F

Precision Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By End-Use, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 184 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2023 年全球精密诊断市场估值为 141.8 亿美元，预计在预测期内将出现令人印象深刻的成长，到 2029 年复合年增长率为 16.48%。

市场概况
预测期 2025-2029
2023 年市场规模 141.8亿美元
2029 年市场规模 351亿美元
2024-2029 年复合年增长率 16.48%
成长最快的细分市场 临床实验室
最大的市场 北美洲

在技​​术进步和对个人化医疗解决方案日益增长的需求的推动下，全球精密诊断市场正在经历强劲增长。精准诊断涉及使用分子诊断、基因检测和其他先进技术来准确检测和表征个体层面的疾病。根据美国国立卫生研究院期刊发表的资料，基因检测在过去二十年中经历了大幅成长。这种扩张导致在美国建立了基因检测登记处，旨在提供有关基因检测和相关实验室的透明资讯。利用基因检测登记处的公开资料，资料强调，截至 2022 年 11 月，美国总共提供了 129,624 项基因检测，全球检测数量为 197,779 项，包括现有检测的更新版本。在 GTR 註册的这些测试中，90% 以上是用于临床而非研究目的。这种方法可以製定量身定制的治疗计划，改善患者的治疗效果并降低医疗成本。市场扩张的主要驱动力包括癌症和糖尿病等慢性疾病发生率的上升，这些疾病需要精确的诊断工具来进行早期检测和有效管理。

人工智慧和机器学习在诊断过程中的整合提高了准确性和效率，促进医疗保健提供者更快地做出决策。该市场的特点是密集的研发活动，旨在推出满足特定患者需求的创新诊断解决方案。从地理位置来看，北美由于强大的医疗基础设施、技术进步和高医疗保健支出而占据市场主导地位。然而，由于医疗保健投资的增加、意识的提高和医疗保健服务范围的扩大，预计亚太地区将显着增长。全球精准诊断市场的主要参与者包括大型诊断公司、生技公司和合作开发尖端诊断技术的学术研究机构。

主要市场驱动因素

分子诊断的技术进步

慢性病发生率上升

主要市场挑战

监管和报销障碍

资料隐私和安全问题

转向个人化医疗

人工智慧与机器学习的融合

细分市场洞察

类型洞察

最终用途见解

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球精密诊断市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型（基因测试、直接面向消费者的测试、深奥测试、其他）
    • 依应用（肿瘤学、呼吸系统疾病、皮肤病、中枢神经系统疾病、免疫学、遗传疾病、其他）
    • 依最终用途（医院、临床实验室、其他）
    • 按公司划分 (2023)
    • 按地区
  • 市场地图

第 6 章：北美精密诊断市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按申请
    • 按最终用途
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 7 章：欧洲精密诊断市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按申请
    • 按最终用途
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第 8 章：亚太地区精密诊断市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按申请
    • 按最终用途
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲

第 9 章：南美洲精密诊断市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按申请
    • 按最终用途
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲精密诊断市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按申请
    • 按最终用途
    • 按国家/地区
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 併购（如有）
  • 产品发布（如有）
  • 最近的发展

第 13 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第14章：竞争格局

  • Abbott Laboratories Inc.
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • bioMerieux SA
  • Becton, Dickinson and Company
  • Danaher Corporation
  • QIAGEN NV
  • Hologic Inc.
  • Agilent Technologies Inc.

第 15 章：策略建议

第16章调查会社について・免责事项

简介目录
Product Code: 24133

Global Precision Diagnostics Market was valued at USD 14.18 Billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 16.48% through 2029.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 14.18 Billion
Market Size 2029USD 35.10 Billion
CAGR 2024-202916.48%
Fastest Growing SegmentClinical Laboratories
Largest MarketNorth America

The Global Precision Diagnostics Market is experiencing robust growth driven by advancements in technology and increasing demand for personalized healthcare solutions. Precision diagnostics involve the use of molecular diagnostics, genetic testing, and other advanced techniques to accurately detect and characterize diseases at an individual level. According to data published in a National Institutes of Health journal, genetic testing has experienced substantial growth over the past two decades. This expansion led to the establishment of the Genetic Testing Registry in the United States, aimed at providing transparent information about genetic tests and associated laboratories. Utilizing publicly accessible data from the Genetic Testing Registry, the data highlights that ,as of November 2022, a total of 129,624 genetic tests were available in the US, with a global count of 197,779 tests, including updated versions of existing tests. More than 90% of these tests registered with the GTR were intended for clinical rather than research purposes. This approach allows for tailored treatment plans, improving patient outcomes and reducing healthcare costs. Key drivers of market expansion include rising incidences of chronic diseases such as cancer and diabetes, which require precise diagnostic tools for early detection and effective management.

The integration of artificial intelligence and machine learning in diagnostic processes enhances accuracy and efficiency, facilitating faster decision-making by healthcare providers. The market is characterized by intense research and development activities aimed at introducing innovative diagnostic solutions that cater to specific patient needs. Geographically, North America dominates the market due to strong healthcare infrastructure, technological advancements, and high healthcare expenditure. However, the Asia-Pacific region is expected to witness significant growth owing to increasing healthcare investments, rising awareness, and expanding access to healthcare services. Key players in the global precision diagnostics market include major diagnostic companies, biotechnology firms, and academic research institutions collaborating to develop cutting-edge diagnostic technologies.

Key Market Drivers

Technological Advancements in Molecular Diagnostics

Technological advancements in molecular diagnostics have profoundly transformed the landscape of disease detection and monitoring in healthcare. Next-generation sequencing (NGS), a pivotal advancement, allows for rapid and comprehensive analysis of genomic sequences. It enables researchers and clinicians to identify genetic mutations, variations, and biomarkers associated with diseases such as cancer, genetic disorders, and infectious diseases. NGS's ability to sequence entire genomes or targeted regions with unprecedented speed and accuracy has revolutionized personalized medicine by enabling tailored treatment strategies based on an individual's genetic profile.

Polymerase chain reaction (PCR) remains another cornerstone in molecular diagnostics, enabling the amplification of specific DNA sequences. PCR's sensitivity and specificity make it invaluable for detecting infectious agents, genetic mutations, and monitoring disease progression. Advancements in PCR technology, such as real-time PCR and digital PCR, have further enhanced its utility in clinical diagnostics, offering faster and more precise results crucial for timely treatment decisions.

Microarray analysis complements these techniques by allowing simultaneous analysis of thousands of genetic variations or biomarkers in a single experiment. This high-throughput capability is particularly advantageous in research settings and clinical diagnostics where screening for multiple genetic markers can aid in disease risk assessment, diagnosis, and prognosis. Continuous investment in research and development (R&D) by companies and academic institutions is pivotal in advancing these diagnostic technologies. Efforts focus on enhancing the sensitivity, specificity, and speed of molecular diagnostics to meet the increasing demand for accurate and timely disease detection. Innovations such as miniaturization, automation, and integration with bioinformatics and AI are driving improvements in diagnostic efficiency and scalability.

As these technologies evolve, their application extends beyond traditional diagnostics to include predictive and preventive healthcare paradigms. They empower healthcare providers with tools to predict disease risks, tailor interventions, and monitor treatment responses at a molecular level. The ongoing convergence of molecular diagnostics with other disciplines such as digital health and precision medicine promises further innovations, underscoring their pivotal role in shaping the future of healthcare delivery.

Rising Incidences of Chronic Diseases

The rising incidence of chronic diseases worldwide, including cancer, cardiovascular disorders, and diabetes, presents a substantial challenge to global healthcare systems and underscores the critical need for advanced diagnostic solutions like precision diagnostics. Chronic diseases are characterized by their prolonged duration and the requirement for ongoing medical management, making accurate and timely diagnosis crucial for effective treatment outcomes. Cancer remains one of the leading causes of death globally, with a diverse array of types and genetic mutations contributing to its complexity. According to the World Health Organization (WHO)'s cancer agency, the International Agency for Research on Cancer (IARC), released the latest estimates of the global burden of cancer. In 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths. The estimated number of people who were alive within 5 years following a cancer diagnosis was 53.5 million. About 1 in 5 people develop cancer in their lifetime, approximately 1 in 9 men and 1 in 12 women die from the disease. Precision diagnostics, leveraging techniques such as next-generation sequencing (NGS) and liquid biopsy, allow clinicians to identify specific genetic alterations and biomarkers that dictate tumor behavior and response to treatment. This molecular-level insight enables personalized therapeutic strategies, including targeted therapies and immunotherapies, tailored to individual patients for improved efficacy and reduced side effects.

Similarly, cardiovascular diseases, encompassing conditions like coronary artery disease, hypertension, and heart failure, benefit from precision diagnostics that assess genetic predispositions, biomarkers of inflammation, and lipid metabolism profiles. Early detection of risk factors and precise monitoring of disease progression help guide personalized interventions such as lifestyle modifications, medication management, and invasive procedures like stent placement or cardiac surgery.

Diabetes, another prevalent chronic condition, encompasses a spectrum of metabolic disorders characterized by elevated blood sugar levels. Precision diagnostics aid in identifying genetic predispositions, autoimmune markers, and individual responses to antidiabetic medications. This enables healthcare providers to optimize treatment plans, ranging from insulin therapy to novel medications targeting specific pathways, thus improving glycemic control and reducing long-term complications.

The increasing burden of chronic diseases not only impacts individual health but also strains healthcare systems globally due to escalating costs associated with disease management and complications. Precision diagnostics offer a promising solution by facilitating early intervention, reducing hospitalizations, and improving patient outcomes through targeted and personalized care approaches.

Key Market Challenges

Regulatory and Reimbursement Hurdles

One of the primary challenges facing the global precision diagnostics market is navigating complex regulatory landscapes and securing adequate reimbursement. Regulatory approval processes for diagnostic tests can be lengthy and stringent, varying significantly between countries and regions. Different regulatory requirements often necessitate separate approvals for each market, delaying the commercialization timeline for new diagnostic technologies.

Reimbursement policies for precision diagnostics can be inconsistent and unpredictable. Insurance coverage and reimbursement rates may vary based on factors such as test efficacy, clinical utility, and cost-effectiveness. The lack of standardized reimbursement guidelines for innovative diagnostic tests often poses financial barriers for healthcare providers and reduces incentives for investment in research and development. As a result, companies may face challenges in achieving widespread adoption of their precision diagnostics despite their clinical benefits, hindering market growth.

Data Privacy and Security Concerns

The rapid advancement and integration of digital health technologies in precision diagnostics bring forth critical concerns regarding the privacy and security of patient data. Precision diagnostics involve the analysis of highly sensitive information, including genomic data and biomarkers, which are pivotal for personalized healthcare decisions. This reliance on such data underscores the importance of adhering to stringent data protection regulations, such as HIPAA in the United States and GDPR in the European Union.

Compliance with these regulations is essential but presents challenges due to the complexity of data management in healthcare settings. Healthcare providers and diagnostic companies must implement robust measures such as data encryption, secure storage systems, stringent access controls, and secure transmission protocols to safeguard patient information from potential threats like cyberattacks or unauthorized access. These protective measures not only mitigate the risk of data breaches but also preserve patient confidentiality and trust. Failure to uphold data privacy standards can have severe consequences, including legal ramifications, financial penalties, and reputational damage to healthcare organizations and diagnostic companies. Breaches in data security can erode patient confidence in precision diagnostics, hindering their widespread adoption and acceptance in clinical practice.

Shift Towards Personalized Medicine

The shift towards personalized medicine marks a paradigmatic evolution in healthcare, moving beyond traditional one-size-fits-all approaches to treatments tailored to the unique genetic, molecular, and environmental profiles of individual patients. Central to this transformation are precision diagnostics, which harness advances in genomics, proteomics, and metabolomics to elucidate intricate biomarkers and molecular signatures crucial for therapeutic decision-making. Genomics plays a pivotal role by unraveling an individual's genetic blueprint, identifying genetic mutations, variations, and predispositions to diseases. This genetic information guides healthcare providers in predicting disease risks, selecting appropriate therapies, and optimizing treatment outcomes. For instance, in oncology, genomic profiling of tumors helps pinpoint specific mutations driving cancer growth, enabling the prescription of targeted therapies that block these aberrant pathways while sparing healthy tissues.

Proteomics and metabolomics complement genomics by offering insights into protein expression patterns and metabolic processes within cells. These disciplines enhance the understanding of disease mechanisms and drug responses, facilitating personalized treatment strategies. By analyzing proteins and metabolites in patient samples, clinicians can tailor interventions to maximize efficacy and minimize adverse effects based on individual biochemical profiles.

The integration of these advanced diagnostic technologies into clinical practice enhances healthcare delivery by promoting precision and efficacy in treatment. Patients benefit from optimized therapeutic regimens that not only address their medical conditions more effectively but also enhance their overall quality of life by reducing treatment-related complications.

The adoption of personalized medicine principles is accelerating globally as healthcare providers recognize its potential to revolutionize patient care. Patients, too, are increasingly embracing personalized approaches that promise treatments aligned with their unique genetic makeup and health characteristics. This growing demand for precision diagnostics underscores the need for continued innovation and investment in diagnostic technologies to expand their accessibility and applicability across diverse clinical settings.

Integration of Artificial Intelligence and Machine Learning

The integration of artificial intelligence (AI) and machine learning (ML) represents a transformative leap forward in precision diagnostics, offering unprecedented capabilities in data analysis and decision-making within the healthcare sector. AI algorithms, powered by ML models, have the capacity to process vast amounts of heterogeneous data, ranging from genomic sequences and medical images to electronic health records (EHRs) and real-time patient monitoring data. In genomic analysis, AI algorithms can sift through massive genomic datasets to identify subtle genetic variations associated with disease susceptibility, progression, and treatment response. By discerning patterns across these data points, AI enhances the accuracy of genetic profiling and enables healthcare providers to deliver personalized treatment plans tailored to individual genetic profiles. This capability is particularly impactful in oncology, where AI-driven genomic analysis aids in selecting targeted therapies that address specific mutations driving cancer growth while minimizing unnecessary treatments.

In medical imaging, AI algorithms excel in interpreting complex imaging data, such as MRI scans, CT scans, and pathology images. Through pattern recognition and deep learning techniques, AI can detect abnormalities, classify lesions, and predict disease progression with high accuracy. This facilitates early detection of diseases like cardiovascular disorders and cancers, enabling timely interventions and improved patient outcomes. AI-powered predictive analytics in clinical settings harness historical patient data from EHRs to forecast disease risks, predict patient outcomes, and optimize treatment strategies. ML models analyze patient demographics, medical history, and treatment responses to generate personalized recommendations for healthcare providers, fostering more informed decision-making and enhancing patient care quality.

The continuous advancement of AI technologies holds promise for further innovation in precision diagnostics, driving market expansion as healthcare systems worldwide seek to leverage these capabilities. Investment in AI and ML research and development is pivotal in refining algorithms, improving computational efficiency, and ensuring the ethical deployment of AI-driven diagnostics in clinical practice.

Segmental Insights

Type Insights

Based on the type, In 2023, in the global precision diagnostics market, genetic tests emerged as the dominant segment. Genetic tests have gained prominence due to their critical role in personalized medicine, offering insights into an individual's genetic makeup and predisposition to certain diseases. Advances in genomics have significantly enhanced the accuracy and affordability of genetic testing, making it more accessible to healthcare providers and patients alike. These tests enable clinicians to identify genetic variations associated with diseases such as cancer, cardiovascular disorders, and rare genetic conditions, thereby facilitating early detection, risk assessment, and personalized treatment strategies.

The growing awareness and acceptance of genetic testing among consumers have fueled market growth. Direct-to-consumer (DTC) genetic tests have gained popularity, allowing individuals to access genetic information related to ancestry, health traits, and disease risks directly from commercial providers. This direct accessibility has democratized genetic testing, empowering individuals to make informed decisions about their health and wellness based on their genetic predispositions.

End-Use Insights

Based on the End-Use, In the global precision diagnostics market, clinical laboratories are anticipated to witness significant growth over the forecast period. Clinical laboratories play a pivotal role in precision diagnostics by performing a wide range of tests, including molecular diagnostics, genetic testing, and specialized assays for various diseases and conditions. These laboratories are equipped with advanced diagnostic technologies and expertise necessary for accurate and reliable testing, which is essential for disease diagnosis, monitoring, and treatment selection.

The increasing demand for precise and timely diagnostic services, driven by the rising prevalence of chronic diseases and the growing emphasis on personalized medicine, is a major factor contributing to the growth of clinical laboratories. As healthcare systems worldwide strive to improve patient outcomes and optimize treatment pathways, there is a heightened need for comprehensive diagnostic testing capabilities offered by clinical laboratories. Technological advancements in diagnostic platforms, automation, and data analytics are enhancing the efficiency and accuracy of testing processes within clinical laboratories. These advancements enable faster turnaround times for test results, improve workflow management, and support the integration of complex diagnostic algorithms and interpretations.

Regional Insights

North America asserted its dominance in the Global Precision Diagnostics Market in 2023, primarily due to several key factors that have propelled the region to hold the largest market share in this rapidly evolving sector. North America benefits from a robust healthcare infrastructure characterized by advanced healthcare facilities, high adoption rates of innovative medical technologies, and substantial investments in research and development. These factors create a conducive environment for the development and commercialization of precision diagnostics, fostering a competitive edge in the global market.

The region boasts a strong regulatory framework that supports the introduction and approval of new diagnostic technologies. Regulatory agencies such as the Food and Drug Administration (FDA) in the United States provide clear pathways for market entry, ensuring rigorous evaluation of safety, efficacy, and clinical utility of precision diagnostics. This regulatory clarity enhances investor confidence and accelerates the commercialization timeline for new diagnostic products.

Key Market Players

Abbott Laboratories Inc.

F. Hoffmann-La Roche Ltd.

Siemens Healthineers AG

Thermo Fisher Scientific Inc.

bioMerieux SA

Becton, Dickinson and Company

Danaher Corporation

QIAGEN N.V.

Hologic Inc.

Agilent Technologies Inc

Report Scope:

In this report, the Global Precision Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Precision Diagnostics Market, By Type:

    Genetic Tests Direct to Consumer Tests Esoteric Tests Others

Precision Diagnostics Market, By Application:

    Oncology Respiratory Diseases Skin Diseases CNS Disorders Immunology Genetic Diseases Others

Precision Diagnostics Market, By End-Use:

    Hospitals Clinical Laboratories Others

Precision Diagnostics Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia-Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Precision Diagnostics Market.

Available Customizations:

Global Precision Diagnostics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Precision Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Genetic Tests, Direct to Consumer Tests, Esoteric Tests, Others)
    • 5.2.2. By Application (Oncology, Respiratory Diseases, Skin Diseases, CNS Disorders, Immunology, Genetic Diseases, Others)
    • 5.2.3. By End-Use (Hospitals, Clinical Laboratories, Others)
    • 5.2.4. By Company (2023)
    • 5.2.5. By Region
  • 5.3. Market Map

6. North America Precision Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By End-Use
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Precision Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End-Use
    • 6.3.2. Mexico Precision Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End-Use
    • 6.3.3. Canada Precision Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End-Use

7. Europe Precision Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By End-Use
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Precision Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End-Use
    • 7.3.2. Germany Precision Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End-Use
    • 7.3.3. United Kingdom Precision Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End-Use
    • 7.3.4. Italy Precision Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End-Use
    • 7.3.5. Spain Precision Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End-Use

8. Asia-Pacific Precision Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By End-Use
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Precision Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End-Use
    • 8.3.2. India Precision Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End-Use
    • 8.3.3. South Korea Precision Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End-Use
    • 8.3.4. Japan Precision Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End-Use
    • 8.3.5. Australia Precision Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End-Use

9. South America Precision Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By End-Use
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Precision Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End-Use
    • 9.3.2. Argentina Precision Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End-Use
    • 9.3.3. Colombia Precision Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End-Use

10. Middle East and Africa Precision Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By End-Use
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Precision Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End-Use
    • 10.3.2. Saudi Arabia Precision Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End-Use
    • 10.3.3. UAE Precision Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End-Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Abbott Laboratories Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. F. Hoffmann-La Roche Ltd.
  • 14.3. Siemens Healthineers AG
  • 14.4. Thermo Fisher Scientific Inc.
  • 14.5. bioMerieux SA
  • 14.6. Becton, Dickinson and Company
  • 14.7. Danaher Corporation
  • 14.8. QIAGEN N.V.
  • 14.9. Hologic Inc.
  • 14.10. Agilent Technologies Inc.

15. Strategic Recommendations

16. About Us & Disclaimer